Cancer Genetics, Inc. CEO Panna Sharma to Participate in Panel at BioNJ CEO Summit

RUTHERFORD, N.J., Oct. 4, 2013 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company"), an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers, today announced its president and CEO, Panna Sharma, will participate in a panel discussion at BioNJ's inaugural CEO Summit from 1:40 p.m. to 2:40 p.m. ET on October 4, 2013 in Bridgewater, New Jersey. The first of its kind summit will bring together chief executive officers and leaders from major biotech and pharmaceutical firms from New Jersey and beyond this fall to share their knowledge, experiences and views on the future in wide-ranging discussions with fellow executives, investors, entrepreneurs, academics and other members of the State's diverse and ever-evolving life sciences community.

The panel discussion, "How Wide is the Crack in the IPO Window," will feature first-hand IPO experiences shared by Mr. Sharma and other panelists from biotech companies such as Chimerix and Omthera Pharmaceuticals that all went public during 2013. In April of 2013, Mr. Sharma successfully led CGI through an IPO and secondary offering in August, raising gross proceeds in excess of $23 million for the Company. CGI is ranked the 8th best biotech IPO of the year and one of the top-20 overall best-performing IPOs for 2013, based on year-to-date returns through the close of trading on October 1, 2013.

Mr. Sharma became a board member and CEO of CGI in May of 2010. Under his tenure, CGI has consistently grown revenues and margins while launching five proprietary DNA-based cancer diagnostics and establishing partnerships and collaborations with leading cancer institutions, including Mayo Clinic, Memorial Sloan-Kettering Cancer Center, and National Cancer Institute. Mr. Sharma also serves on the board of CGI's joint venture in next-generation sequencing with the Mayo Clinic, Oncospire Genomics, based in Rochester, Minnesota.

Prior to CGI, Mr. Sharma was at TSG Partners, a specialty life sciences consultancy and advisory company, from 2001 to 2010, where he was the Managing Partner and founder. At TSG he led the development of strategic initiatives, corporate growth strategy and corporate turnarounds for both public and private companies. He also led over 70 buy- and sell-side transactions for life sciences, healthcare and biopharma companies. At TSG, he established the Global Diagnostics Index, the Global Biotools Index and several other life science capital markets indices that are still used in the life science industry.

Prior to founding TSG, Mr. Sharma was the Chief Strategy Officer for iXL Enterprises, Inc. ("iXL"), a public e-business consultancy where he led strategy development and acquisitions activity and was part of the management team that aided in taking the company public in June 1999.

The BioNJ CEO Summit will take place at the Bridgewater Marriott in Bridgewater, New Jersey. To register, please visit

About Cancer Genetics:

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers. These cancers include hematological, urogenital and HPV-associated cancers. The Company's comprehensive range of oncology-focused tests and laboratory services provide critical genomic information to healthcare professionals, cancer centers, and biopharma companies. Through its CLIA certified and CAP accredited state-of-the-art reference lab, Cancer Genetics services some of the most prestigious medical institutions in the world and has strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights and other risks discussed in the Company's Form 10-Q for the quarter ended June 30, 2013 and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

CONTACT: Investor Relations RedChip Companies, Inc. Jon Cunningham, 800-733-2447, ext. 107 jon@redchip.comSource:Cancer Genetics